AJJ Medtech Holdings (SGX:584) EBIT: S$-3.17 Mil (TTM As of Mar. 2026)


What is AJJ Medtech Holdings EBIT?

AJJ Medtech Holdings SGX:584 EBIT is S$-3.17 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

AJJ Medtech Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was S$-0.55 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was S$-3.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AJJ Medtech Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was -77.17%. AJJ Medtech Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -199.45%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. AJJ Medtech Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -35.40%.

AJJ Medtech Holdings  (SGX:584) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AJJ Medtech Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-2.18 * ( 1 - 0% )/( (3.194 + 2.456)/ 2 )
=-2.18/2.825
=-77.17 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.545 - 3.523 - ( 0.414 - max(0, 5.414 - 2.242+0.414))
=3.194

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.762 - 3.948 - ( 0.107 - max(0, 5.208 - 1.566+0.107))
=2.456

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

AJJ Medtech Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.18/( ( (1.144 + max(-2.061, 0)) + (1.042 + max(-2.489, 0)) )/ 2 )
=-2.18/( ( 1.144 + 1.042 )/ 2 )
=-2.18/1.093
=-199.45 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.652 + 1.001 + 0.108) - (3.523 + 0 + 0.299)
=-2.061

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.481 + 0.978 + 0) - (3.948 + 0 + 0)
=-2.489

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

AJJ Medtech Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-3.167/8.946
=-35.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AJJ Medtech Holdings EBIT Related Terms

AJJ Medtech Holdings EBIT Historical Data

* Premium members only.

The historical data trend for AJJ Medtech Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AJJ Medtech Holdings EBIT Chart

AJJ Medtech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.66 -3.93 -2.50 -3.82 -2.84

AJJ Medtech Holdings Quarterly Data
Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.66 -0.78 -1.18 -0.55

SGX:584 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, AJJ Medtech Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AJJ Medtech Holdings EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AJJ Medtech Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AJJ Medtech Holdings's EV-to-EBIT falls into.


AJJ Medtech Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-3.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of S$-3.17 Mil mean?
AJJ Medtech Holdings (SGX:584) has a EBIT of S$-3.17 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AJJ Medtech Holdings.
Is AJJ Medtech Holdings' EBIT too high?
AJJ Medtech Holdings' current EBIT is S$-3.17 Mil.
How does AJJ Medtech Holdings' EBIT compare to ABT and SYK?
AJJ Medtech Holdings' EBIT of S$-3.17 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AJJ Medtech Holdings. AJJ Medtech Holdings's current EBIT is S$-3.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AJJ Medtech Holdings stock overvalued right now?
Based on GuruFocus' analysis, AJJ Medtech Holdings (SGX:584) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.01, compared to a current price of S$0.00 — trading 60% below its estimated fair value. The current EBIT is S$-3.17 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For AJJ Medtech Holdings (SGX:584), the current EBIT is S$-3.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AJJ Medtech Holdings Business Description

Address 8 Commonwealth Lane, No. 02-04, Grande Building, Singapore, SGP, 149555
AJJ Medtech Holdings Ltd is a healthcare technology company building an integrated platform across medical devices, digital systems, and intelligent care infrastructure in Singapore, Southeast Asia, and selected international markets. It integrates artificial intelligence, robotics, and healthcare systems to support healthcare delivery across the patient care continuum. Its portfolio includes diagnostic systems, medical and dental devices, consumables, digital and robotics-enabled healthcare solutions, and turn-key supply-chain solutions. Its segments are corporate and investment holding, healthcare products and services, and healthcare digital products, which generate maximum revenue. It operates mainly in Singapore, and its revenue is derived from the sale of medical healthcare products.